Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?

摘要

A significant proportion of patients with atrial fibrillation (AF) un- dergo percutaneous coronary intervention (PCI) [1]. Use of triple anti- thrombotic therapy (TAT) in patients with AF undergoing PCI contributes to increased bleeding risk [2]. The optimum choice of anti- thrombotic therapy in patients with AF undergoing PCI is unclear, given the need for anticoagulation to prevent stroke, and antiplatelet therapy to prevent myocardial infarction (MI) and stent thrombosis [3].